Palvella Therapeutics, Inc. Additional Paid in Capital, Common Stock
Palvella Therapeutics, Inc. (PVLA) had Additional Paid in Capital, Common Stock of $316.25 million as of 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2022-08-04
- 2022-06-30: Additional Paid in Capital, Common Stock $316.25M.
- 2022-03-31: Additional Paid in Capital, Common Stock $314.67M.
- 2021-12-31: Additional Paid in Capital, Common Stock $307.00M.
- 2021-09-30: Additional Paid in Capital, Common Stock $302.59M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2022-06-30 | $316.25M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $314.67M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $307.00M 10-Q · filed 2022-08-04 | |
| 2021-09-30 | $302.59M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $277.50M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $253.56M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $242.67M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $241.42M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $230.41M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $228.75M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $227.47M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $194.69M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $192.96M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $191.22M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $189.93M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $188.64M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $187.07M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $185.64M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $136.48M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $134.80M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $132.13M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $130.10M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $129.35M 10-K · filed 2018-03-15 | $129.35M 10-K · filed 2017-03-30 |
| 2016-09-30 | $128.87M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $128.48M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $112.60M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $112.23M 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |